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Abstract Previous studies have demonstrated sialyltransferase 
(ST) enzyme activity to be induced in hepatic cells by 
corticosteroids. In this study, we used the H411e rat hepatoma 
cell line to further characterise this induction with particular 
reference to the subsequent changes in the pattern of sialogly-
coprotein (SGP) expression. The induction of total ST activity 
by dexamethasone was concentration dependent with maximum 
induction occurring 12 h subsequent to drug addition. Western 
blot analysis demonstrated that the induction was associated with 
an increase in the expression of the a2,6(N) ST enzyme with no 
change in the expression levels of the cc2,3(N) enzyme. While the 
induction resulted in an increase in the reaction velocity (Fmox) 
of the enzyme for both the sugar donor (CMP-Neu5Ac) and the 
asialofetuin acceptor protein, there was no significant change in 
the enzyme affinity (Km) for the substrates, suggestive of either 
an increase in the expression or efficiency of the existing 
enzyme(s) rather than an induction of novel ST enzymes. Lectin 
blot analysis of cellular glycoprotein expression demonstrated no 
change in the expression patterns of either OL2,3 or oc2,6-linked 
SGP following enzyme induction. These results suggest that the 
available acceptor sites for the terminal sialic acid group(s) may 
be fully occupied in the control cells and therefore there are no 
further sites onto which the sialic acid can be transferred 
following induction of ST enzyme activity. This may be due to 
the high basal enzyme levels in the control cells already 
exhausting endogenous acceptor sites. 
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1. Introduction 
Glycoproteins form a diverse group of complex macromol-
ecules which are probably best defined as conjugated proteins 
which contain one or more heterosaccharides as their pros-
thetic group covalently bound to the polypeptide chain [1]. 
Glycosylation can be considered as one of the most common 
and diverse covalent modifications undertaken by newly syn-
thesised proteins with this diversity lying in both the amino 
acids that are modified and the structures attached [2]. Sialyl-
transferases (ST) belong to the subclass of glycosyltransferases 
that catalyse the transfer of activated sialic acid (CMP-Neu5-
Ac) to terminal positions on the carbohydrate chains of sia-
loglycoproteins (SGP) and glycolipids (GL). The ST family 
comprises up to 19 enzymes all of which would be required 
to synthesise the sialyloligosaccharide sequences known to 
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date, with each enzyme being distinguished on the basis of 
both its specificity for the sequence and the anomeric linkage 
formed between the sialic acid and the acceptor oligosaccha-
ride [3,4]. It is worthy of note that, because of its size and 
negative charge, Neu5Ac is considered as one of the most 
important constituents of the carbohydrate moiety of many 
glycoconjugates [5]. 
ST expression has been shown to be induced in hepatic cells 
by the synthetic glucocorticoid dexamethasone (dex) both 
in vivo [6,7] and in vitro [8]. The observed increases in 
the ST mRNA levels are achieved through transcriptio-
nal enhancement [8] with increased stabilisation of the exis-
ting mRNA not appearing to play a role [8,9]. This induc-
tion appears to be relatively selective for the oc2,6(N) ST en-
zyme (E.C. 2.4.99.1), which catalyses the transfer sialic 
acid onto the Gal residue of an N-linked oligosaccharide 
chain [10], and the induction also displays a cell-type specific-
i ty[ l l ] . 
Considering that SGP and GL both play an important role 
in cell structure and function, conditions altering cellular ST 
activity and hence sialylation would be expected to have a 
profound influence on cell function [5]. While particular inter-
est has been shown to date in the effects of dex on hepatic cell 
ST enzyme activity, there is little data available on the bio-
chemical consequences of this induction. The aim of this study 
was, therefore, to gain a greater understanding of this induc-
tion of ST by dex using the H41 le hepatoma cell line, as an in 
vitro model system, with particular interest in the subsequent 
expression of the resultant SGP species. 
2. Materials and methods 
2.1. Cell culture 
H411e rat hepatoma cells (American Type Culture Collection) were 
cultured routinely in Dulbecco's modified Eagle's medium containing 
10% fetal calf serum (FCS), 1% (v/v) penicillin and 1% (v/v) strepto-
mycin as previously described [12]. Cells were split (passaged) by 
trypsinisation and re-seeded at a density of 7.5 X 105 cells per 75 cm2 
flask. The cells were harvested by scraping in phosphate buffered 
saline solution (PBS), centrifuged for 10 min at 3000 rpm and re-
suspended in water by sonication. The protein content of the samples 
was quantified using the Folin phenol reagent [13]. For analysis 
of released SGP, the cells were incubated in serum-free medium for 
2 h to remove serum-derived glycoproteins and then incubated in 
fresh serum-free medium for 18 h. At this stage, there was no evidence 
of cell death or the dislodgement of cells from the culture substrate. 
The medium was then collected, centrifuged at 15 000Xg for 10 min 
to remove any cell debris and stored at —20°C until use. All of 
the biochemical assays were carried out at least in duplicate on at 
least three sets of individually harvested cells of increasing passage 
number. 
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2.2. Sialyltransferase assay 
Total sialyltransferase activity was determined as previously de-
scribed [14] using cytidine-5-monophosphate-4,5,6,7,8,9[14C]N-acetyl-
neuraminic acid (CMP[14C]Neu5Ac, Radiochemical Centre, Amer-
sham; specific activity 293 mCi/mmol) as the sialic acid donor and 
asialofetuin (ASF; Sigma), which did not contain any detectable re-
sidual sialic acid, as an exogenous acceptor. Under the assay condi-
tions used, there was minimal transfer of sialic acid to endogenous 
protein acceptors as has previously been reported [15]. 
2.3. Determination of enzyme kinetic parameters 
In order to determine the kinetic parameters of the enzyme, ST 
activity was assayed using varying concentrations of ASF and 
CMP-Neu5Ac. The kinetic parameters, Km and Fmax, were calculated 
using the Enzfit programme for enzyme kinetics [16]. 
2.4. Sialoglycoprotein analysis 
Glycoconjugate expression was determined by lectin blot analysis as 
previously described [17], Briefly, the individual peptides of 50ug pro-
tein samples were separated by discontinuous SDS polyacrylamide gel 
electrophoresis and transferred to PVDF membranes (Millipore) by 
electroblotting. Glycoproteins containing sialic acid attached to Gal 
residues in a2,3-linkages and to Gal/GalNAc residues in oc2,6-linkages 
were detected using the MAA and SNA lectins, respectively, and 
visualised using the DIG Glycan Differentiation Kit (Boehringer 
Mannheim). 
2.5. Sialyltransferase enzyme expression 
The expression of the a2,3(N) and a2,6(N) ST enzymes were de-
termined using antisera raised against the individual enzymes. The 
antiserum to rat rx2,6(N) ST has been described previously [18]; a 
new rabbit polyclonal antiserum has been raised to a fusion protein 
consisting of fi-galactosidase fused with full length Jurkat cell-derived 
a2,3(N) ST and expressed in E. coli. [19]. The fusion protein was 
solubilized from inclusion bodies as described previously [20], sepa-
rated on SDS-PAGE and injected into a rabbit. The resulting anti-
serum was found to be monospecific to a soluble form of the enzyme 
expressed in Sf9 cells using the baculovirus expression system (kindly 
provided by Dr. M. Streiff, Novartis); characterization included ELI-
SA, immunofluorescence of recombinant antigen expressed in COS 
cells and immunoblotting (Burger et al., submitted for publication). 
In all tissue cultured cells investigated by immunofluorescence the 
antiserum produced a typical Golgi staining pattern. The antiserum 
proved to be crossreactive with rat and mouse enzyme. The protein 
components of the H41 le cell pellets were separated by SDS-PAGE 
and transferred to PVDF membranes as described and the binding of 
the ST antisera was detected using the ECL detection system (Amer-
sham). The autoradiographs were scanned using a Glyco FACE imag-
ing system and the immunoreactive bands were quantified by densito-
metric analysis using the NIH Image software package. The staining 
intensities of the blots were proportional to the protein loaded within 
the range employed in the assay (data not shown) and the variability 
between samples was less than 5% (see Fig. 3). 
3. Results and discussion 
There was a dose-related induction of total cellular ST ac-
tivity in the H411e cells by dex, with maximum induction 
being reached at [10~7 M] (Fig. la). A lag period of approx-
imately 3 h after drug addition was observed prior to enzyme 
induction, with the plateau being reached at 12 h after treat-
ment with dex (Fig. lb). The dose-response relationship be-
tween dex and cellular ST activity were in good agreement 
with those previously reported for hepatic cells [8,9] and in-
dicated that the H411e cells have a significant capacity for ST 
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Fig. 1. (a) Dose-response effect of dex on the ST activity of H411e 
cells treated with drug for 24 h prior to harvesting, (b) Time course 
of ST induction by dex (10- 6 M). The cells were plated at 104 cells/ 
cm2 and treated at time 0 (24 h post plating) with dex. The cells 
were harvested at the indicated time points and the cellular ST ac-
tivity determined. Values represent mean ± S.E.M. (n = 3). 
enzyme induction subsequent to drug addition. This is an 
important observation as agents including cytokines and glu-
cocorticoids act synergistically in vivo to raise the levels of 
many glycoproteins during the acute phase response [6]. The 
presence of this reserve capacity for induction would suggest 
that the H411e cells appear to be a good model for in vivo 
hepatocyte function where dex induction of ST activity has 
also been observed [7]. The lag period of approximately 3 h 
between the addition of drug and the induction effect was in 
agreement with previous reports that dex causes a transcrip-
tional enhancement of ST mRNA [8]. This was supported by 
the observation that the activity of the enzyme in the dex 
treated cells remained significantly above control levels for 
at least 24 h after the withdrawal of the drug and the direct 
addition of dex to the enzyme assay had no direct effect on 
the activity (data not shown). 
The kinetics of enzyme induction were then determined by 
independently varying the concentrations of the CMP-Neu5-
Ac sialic acid donor and the asialofetuin acceptor. For the 
control cells, when the concentrations of CMP-Neu5Ac were 
varied, the kinetic parameters were calculated as 
Km = 0.068 ±0.039 mM and Fmax = 3.35 ±0.414 pmol/mg per 
hour following Lineweaver-Burk analysis (Fig. 2a). Upon 
treatment with dexamethasone, the Km was calculated as 
Fig. 2. The effect of dex treatment on the ST enzyme kinetics. Cells were cultured as described and assayed for ST activity using (a) increasing 
concentrations of CMP-Neu5Ac [0.05 mM] to [2 mM] in the presence of 1 mg ASF and (b) increasing concentrations of ASF [0.125 mg/ml] to 
[10 mg/ml] in the presence of 1 mM CMP-Neu5Ac. The values represent mean ± S.E.M. (n = 3) and the kinetic parameters were calculated by 
Lineweaver-Burk analysis. 
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Fig. 3. The expression of the (A) a2,3 and (B) a2,6 ST enzymes in the H411e cells following treatment with dex [10 8 M] for 24 h as deter-
mined by Western blot analysis. Graphs represent mean ± S.E.M. (n = 3) of densitometric values. 
0.144 ±0.022 mM (mean ± standard deviation) and the Kmax 
as 15.5 ±0.65 pmol/mg per hour. The increase in the latter 
parameter was calculated as being significant upon analysis 
using the Enzfit programme. A constant concentration of 
CMP-Neu5Ac (1.0 mM), which was significantly in excess 
of the Km value so as not to act as a limiting factor, 
was then used to determine the kinetic parameters of the 
ASF acceptor (Fig. 2b). A saturation effect was observed 
for ASF at concentrations above 5 mg/ml and the substrate 
was shown to act as an inhibitor of ST activity at a concen-
tration of 10 mg/ml (Fig. 2b). The kinetic parameters for 
ASF, as determined again by Lineweaver-Burk analysis, 
were Km = 7.79 ± 2.32 X 10
- 2 mg/ml and Kmax = 0.70 ±0.58 
pmol/mg per hour for the untreated cells, and Km = 
13.2 ± 5.51 X10"2 mg/ml and Kmax = 18.10 ±2.43 pmol/mg 
per hour, following administration of dex [10~8 M]. Statistical 
analysis demonstrated that Vmax was the only parameter sig-
nificantly altered following dex administration. The change in 
the enzyme Fmax for the sialic acid donor and the protein 
acceptor would suggest that the observed increase in ST ac-
tivity was due to the induction of the levels of the enzyme 
species. It is unlikely that there was an induction of a novel 
ST species as the affinity for ASF was shown to be unaffected 
by dex induction of the enzyme. 
The contribution of individual ST enzymes to the increase 
in enzyme activity was then determined using enzyme-specific 
antisera (Fig. 3). The antiserum directed against the a2,6(N) 
ST labelled a protein band of 50 kDa which is in good agree-
Fig. 4. The effect of dex treatment on the expression of cellular (a) a2,6- and (b) a2,3-linked SGPs and the release of secreted (c) a2,6- and 
(b) a2,3-linked SGPs from the H411e cell line. The migration of the molecular weight standards (in kDa) are indicated. The standards used 
were myosin (200 kDa), |3 galactosidase (116 kDa), phosphorylase B (97 kDa), albumin (66 kDa) and ovalbumin (45 kDa). 
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ment with previous reports [18]. The increase in the expression 
levels of this protein band closely mirrored the increase in 
total cellular ST levels following dex induction. The antiserum 
directed against the cc2,3(N) ST labelled a protein doublet 
with a major band at 52 kDa and a minor band at 54 kDa. 
There was no change in the density of either band following 
dex treatment. While these results are in good agreement with 
previous reports of ot2,6(N) ST induction in hepatoma cells by 
corticosteroids [10], this is the first confirmation that there is 
no induction of the a2,3(N) ST by dexamethasone. Further-
more, these results support the hypothesis of an induction of 
an endogenous enzyme species, as suggested by the enzyme 
kinetic parameters. 
Having characterised the induction of ST by dex in the 
H411e cells, the expression of both cellular (Fig. 4a,b) and 
secreted (Fig. 4c,d) oc2,6 and oc2,3 SGPs were analysed using 
the SNA and MAA lectins which detect sialic acid linked to 
Gal/GalNAc and Gal residues in a2,6 and oc2,3 linkages, re-
spectively. In all cases, a variety of stained bands were de-
tected indicating the expression of a large number of SGP 
species of diverse molecular size. However, while the induc-
tion of a2,6ST activity by dex did not alter the general pattern 
of lectin staining of either the cellular or secreted SGP species, 
there was a dose-related increase in both SNA and MAA 
labelling of a 66-kDa cellular protein (Fig. 4a,b). Because 
this effect was observed for both lectins, despite dex inducing 
an increase in the oc2,6 ST enzyme alone, it is likely that this 
effect was due to a dex-induction of the protein backbone thus 
providing an increase in the substratum available for sialic 
acid transfer. 
Therefore, although there was a significant increase in ST 
activity, primarily associated with the a2,6(N) ST enzyme, 
there were no general changes in the SGP expression pattern 
as determined by lectin blot analysis apart from that due to an 
increase in the levels of an individual protein backbone. As 
hepatoma cells have a very high endogenous ST activity [7], it 
could be proposed that the majority of the available penulti-
mate Gal acceptor residues are already occupied under nor-
mal cellular conditions and thus, there would be no free ac-
ceptor sugar sites onto which to transfer the sialic acid 
following the dex-induced increase in ST activity. The fact 
that changes in neural SGP levels have been detected in 
vivo following induction of cellular ST activity [21] may be 
explained by the fact that the basal neural enzyme activity is 
considerably lower than hepatic tissue and therefore the pe-
nultimate Gal residues are not saturated with endogenous 
sialic acid [7]. Furthermore, we must consider that the 
H411e cell line has a tumor base and as metastatic cells 
have been reported to have an increase in cell surface sialic 
acid [22], this may also contribute to the saturation of the 
acceptor sugar residues. The lack of effect of increased enzyme 
activity on SGP expression may also be due to changes in the 
rate of turnover of SGP within the cell with a change in 
protein metabolic rate possibly masking the increase in sialyl-
transferase activity. 
While the dex-induced increase in cellular a2,6(N) expres-
sion in hepatoma cells does not appear to alter the sialylation 
state of cellular or secreted SGP, subtle changes in protein 
sialylation, which were undetectable by the lectin blot analy-
sis, cannot be ruled out. Furthermore, previous studies have 
demonstrated that dex treatment of H411e hepatoma cells 
also results in an increase in secreted enzyme [18] although 
it did not prove possible to assay secreted enzyme levels using 
this in vitro system. While the function of the soluble form of 
ST has not been clarified, it will be interesting to investigate 
the functional consequences of an increase in serum ST fol-
lowing dex induction of hepatic ST. 
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